- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- linagliptin QD (once daily) for 7 days
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 6
- States / cities
- Cypress, California • DeLand, Florida • Miami, Florida + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 721–744
of 16,003
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pregnancy, Unexplained Infertility
- Interventions
- Letrozole (aromatase inhibitor), Clomiphene Citrate, Follicle Stimulating Hormone (gonadotropin)
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • San Francisco, California • Stanford, California + 11 more
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- Interleukin-15 Superagonist (N-803), CIML NK cell Infusion, Ipilimumab, Cetuximab
- Drug · Biological
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Non-small Cell Lung Cancer, EGFR-mutant Lung Cancers
- Interventions
- osimertinib, Bevacizumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- HIV, Combination Therapy
- Interventions
- Atazanavir, Ritonavir (heat-stable), Raltegravir, Tenofovir/Emtricitabine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Palm Springs, California • San Francisco, California + 5 more
- Conditions
- HER-2 Positive Metastatic Breast Cancer
- Interventions
- Docetaxel, Trastuzumab, Erythromycin Breath Test (ERMBT)
- Drug · Procedure
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2005
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
- Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Yuba City, California • Centennial, Colorado + 7 more
- Conditions
- Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma, Stage IV Anal Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 55
- States / cities
- Los Angeles, California • Sacramento, California • Aurora, Colorado + 43 more
- Conditions
- Pancreatic Cancer
- Interventions
- Abraxane
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Milk Allergy
- Interventions
- Lactobacillus GG, Extensively Hydrolyzed Casein Formula, Amino Acid Formula
- Dietary Supplement
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- Up to 120 Days
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Woburn, Massachusetts
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- motavizumab (MEDI-524), palivizumab
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- Up to 24 Months
- Enrollment
- 6,635 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 120
- States / cities
- Birmingham, Alabama • Pike Road, Alabama • Phoenix, Arizona + 98 more
- Conditions
- Metastatic Melanoma
- Interventions
- Bempegaldesleukin (NKTR-214), Nivolumab, ⁸⁹Zr-Df-IAB22M2C
- Biological · Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Duarte, California • Portland, Oregon • Philadelphia, Pennsylvania
- Conditions
- Leukemia
- Interventions
- aldesleukin, therapeutic allogeneic lymphocytes, cyclophosphamide, fludarabine phosphate, in vitro treated peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Postpartum Hemorrhage
- Interventions
- Sublingual Misoprostol, IV Oxytocin
- Drug
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,358 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Major Depression
- Interventions
- Tranylcypromine, Dextroamphetamine, Triiodothyronine
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Head and Neck Cancer
- Interventions
- Nivolumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive, Invasive Breast Carcinoma, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IA Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
- Interventions
- Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Radiation Therapy, Therapeutic Conventional Surgery, Trastuzumab
- Drug · Other · Radiation + 2 more
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 4
- States / cities
- Bellevue, Nebraska • Grand Island, Nebraska • Omaha, Nebraska
- Conditions
- Breast Cancer
- Interventions
- Pegylated Liposomal Doxorubicin (Doxil)
- Drug
- Lead sponsor
- Aptium Oncology Research Network
- Network
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 9
- States / cities
- Burbank, California • Los Angeles, California • Palm Springs, California + 6 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- VELCADE™ (bortezomib) for Injection (formerly PS-341)
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 15 more
- Conditions
- Falling Injury, Nutrition Disorder
- Interventions
- Data Collection prior to first fall for all fallers, Hgb value, Vitamin D, C-Reactive Protein
- Other
- Lead sponsor
- Louis Stokes VA Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Pregnancy, Labor
- Interventions
- Misoprostol, Pitocin
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- New York, New York • The Bronx, New York
- Conditions
- Metastatic Malignant Female Reproductive System Neoplasm, Platinum-Resistant Malignant Female Reproductive System Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Refractory Malignant Female Reproductive System Neoplasm
- Interventions
- Durvalumab, Internal Radiation Therapy, Tremelimumab
- Biological · Radiation
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate, Lamivudine and Zidovudine, Cyclosporine, Hepatitis A Vaccine (Inactivated), Efavirenz, Pneumococcal Conjugate Vaccine, Heptavalent, Rabies Vaccine
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2006
- U.S. locations
- 15
- States / cities
- Sacramento, California • Miami, Florida • Chicago, Illinois + 8 more
- Conditions
- Schizophrenia
- Interventions
- D-cycloserine, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts